Wen Yi Ding

Wen Yi Ding

Auto-generated profile, based on publicly available information

Wen Yi Ding

Bristol Renal, Bristol Medical School, University of Bristol, Bristol, United Kingdom; and Department of Paediatric Nephrology, Bristol Royal Hospital for Children, Bristol, United Kingdom

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Kidney International
Verified
Journal Article
Closed access
ABAgnieszka Bierzynska
Agnieszka Bierzynska
HMHugh J. McCarthy
Hugh J. McCarthy
KSKatrina Soderquest
Katrina Soderquest
ESEthan S. Sen
Ethan S. Sen
ECElizabeth Colby
Elizabeth Colby
MSMoin Saleem
Moin Saleem

1 June 2014 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
WDWen Y. Ding
Wen Y. Ding
AKAnia Koziell
Ania Koziell
HMHugh J. McCarthy
Hugh J. McCarthy
ABAgnieszka Bierzynska
Agnieszka Bierzynska
MBMurali K. Bhagavatula
Murali K. Bhagavatula
MSMoin Saleem
Moin Saleem
Of children with idiopathic nephrotic syndrome, 10%-20% fail to respond to steroids or develop secondary steroid resistance (termed initial steroid sensitivity) and the majority progress to transplantation. Although 30%-50% of these patients suffer disease recurrence after transplantation, with poor long-term outcome, no reliable indicator of recurrence has yet been identified. Notably, the incidence of recurrence after transplantation appears reduced in patients with steroid-resistant nephrotic syndrome (SRNS) due to monogenic disorders. We reviewed 150 transplanted patients with SRNS to identify biomarkers that consistently predict outcome of SRNS after transplantation. In all, 25 children had genetic or familial SRNS and did not experience post-transplant recurrence. We reviewed phenotypic factors, including initial steroid sensitivity, donor type, age, ethnicity, time to ESRD, and time on dialysis, in the remaining 125 children. Of these patients, 57 (45.6%) developed post-transplant recurrence; 26 of 28 (92.9%) patients with initial steroid sensitivity recurred after transplantation, whereas only 26 of 86 (30.2%) patients resistant from the outset recurred (odds ratio, 30; 95% confidence interval, 6.62 to 135.86; P<0.001). We were unable to determine recurrence in two patients (one with initial steroid sensitivity), and nine patients did not receive initial steroids. Our data show that initial steroid sensitivity is highly predictive of post-transplant disease recurrence in this pediatric patient population. Because a pathogenic circulating permeability factor in nephrotic syndrome remains to be confirmed, we propose initial steroid sensitivity as a surrogate marker for post-transplant recurrence.

21 June 2010 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
WDWen Yi Ding
Wen Yi Ding
CLChew Kek Lee
Chew Kek Lee
SCSiew Eng Choon
Siew Eng Choon

9 August 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
WDWen Y. Ding
Wen Y. Ding
VKValeryia Kuzmuk
Valeryia Kuzmuk
SHSarah Hunter
Sarah Hunter
ALAbigail Lay
Abigail Lay
BHBryony Hayes
Bryony Hayes
MSMoin Saleem
Moin Saleem
Gene therapy for kidney diseases has proven challenging. Adeno-associated virus (AAV) is used as a vector for gene therapy targeting other organs, with particular success demonstrated in monogenic diseases. We aimed to establish gene therapy for the kidney by targeting a monogenic disease of the kidney podocyte. The most common cause of childhood genetic nephrotic syndrome is mutations in the podocyte gene NPHS2 , encoding podocin. We used AAV-based gene therapy to rescue this genetic defect in human and mouse models of disease. In vitro transduction studies identified the AAV-LK03 serotype as a highly efficient transducer of human podocytes. AAV-LK03–mediated transduction of podocin in mutant human podocytes resulted in functional rescue in vitro, and AAV 2/9–mediated gene transfer in both the inducible podocin knockout and knock-in mouse models resulted in successful amelioration of kidney disease. A prophylactic approach of AAV 2/9 gene transfer before induction of disease in conditional knockout mice demonstrated improvements in albuminuria, plasma creatinine, plasma urea, plasma cholesterol, histological changes, and long-term survival. A therapeutic approach of AAV 2/9 gene transfer 2 weeks after disease induction in proteinuric conditional knock-in mice demonstrated improvement in urinary albuminuria at days 42 and 56 after disease induction, with corresponding improvements in plasma albumin. Therefore, we have demonstrated successful AAV-mediated gene rescue in a monogenic renal disease and established the podocyte as a tractable target for gene therapy approaches.

27 April 2012 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
WDWen Y. Ding
Wen Y. Ding
MSMoin Saleem
Moin Saleem
Nephrotic syndrome is a disorder of the glomerular filtration barrier, and central to the filtration mechanism of the glomerular filtration barrier is the podocyte. We are starting to better understand how this cell, with its unique architectural features, fulfils its exact filtration properties. The multiprotein complex between adjacent podocyte foot processes, the slit diaphragm, is essential to the control of the actin cytoskeleton and cell morphology. Many of the proteins within the slit diaphragm, including nephrin, podocin, transient receptor potential-6 channel, and α-actinin-4, have been identified via genetic studies of inherited nephrotic syndromes. Signaling from slit diaphragm proteins to the actin cytoskeleton is mediated via the Rho GTPases. These are thought to be involved in the control of podocyte motility, which has been postulated as a focus of proteinuric pathways. Nephrotic syndrome is currently treated with immunosuppressive therapy, with significant adverse effects. These therapies may work in nephrotic syndrome due to specific effects on the podocytes. This review aims to describe our current understanding of the cellular pathways and molecules within the podocyte relevant to nephrotic syndrome and its treatment. With our current knowledge of the cellular biology of the podocyte, there is much hope for targeted therapies for nephrotic syndromes.

12 December 2022 in Journal of Paediatrics and Child Health
Verified
Journal Article
Closed access
MHMatthew Harmer
Matthew Harmer
VNVeronica Nijloveanu
Veronica Nijloveanu
ETEftychia Thodi
Eftychia Thodi
WDWen Y Ding
Wen Y Ding
CLCatherine Longthorpe
Catherine Longthorpe
CPCaroline Platt
Caroline Platt